Zai Lab Ltd Stock News

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical co

Zai Lab Limited (NASDAQ:ZLAB) shares gapped down prior to trading on Wednesday . The stock had previously closed at $69.23, but opened at $67.00. Zai Lab shares last traded at $66.67, with a volume of 418 shares traded. A number of research firms have recently commented on ZLAB. Citigroup boosted their price objective on Zai []

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutic

Zai Lab Limited (NASDAQ:ZLAB) fell 8.6% on Monday . The company traded as low as $66.59 and last traded at $66.98. 12,619 shares were traded during trading, a decline of 98% from the average session volume of 540,355 shares. The stock had previously closed at $73.31. A number of research firms have weighed in on []

Sumitomo Mitsui Trust Holdings Inc. lessened its stake in Zai Lab Limited (NASDAQ:ZLAB) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 196,855 shares of the companys stock after selling 3,129 shares during the quarter. Sumitomo Mitsui Trust Holdings []

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutic

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that its partner argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. These patients represent approximately 85% of the total gMG population 1 . With this regulatory milestone, VYVGART is the first and only FDA-approved neonatal Fc receptor (FcRn) blocker.

Zai Lab Limited (NASDAQ:ZLAB) shares were up 12.8% on Thursday . The company traded as high as $62.47 and last traded at $61.95. Approximately 3,933 shares were traded during trading, a decline of 99% from the average daily volume of 527,549 shares. The stock had previously closed at $54.90. Several research analysts have recently commented []

Paratek earns $6 million milestone payment from Zai Lab Paratek earns $6 million milestone payment from Zai Lab

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional Approval For Kidney Inflammation Disease Drug Calliditas Therapeutics AB (

The China National Medical Products Administration (NMPA) has approved Zai Lab Limited''s (NASDAQ: ZLAB ) Nuzyra (omadacycline), a novel antibiotic with both oral and intravenous (IV) formulations. The approval covers the treatment of community-acquired Full story available on Benzinga.com

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline

NUZYRA demonstrated efficacy against common pathogens in three Phase 3 studies, including pathogens resistant to other antibiotic classes as a potential best-in-class tetracycline NUZYRA is Zai Labs fourth new product approval and the first outside oncology SHANGHAI, SAN FRANCISCO, and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused,

Zai Lab (NASDAQ:ZLAB) had its target price trimmed by JPMorgan Chase & Co. from $189.00 to $136.00 in a research note released on Wednesday morning, PriceTargets.com reports. The firm currently has an overweight rating on the stock. Several other research firms also recently weighed in on ZLAB. Zacks Investment Research downgraded shares of Zai Lab [] The post Zai Lab (NASDAQ:ZLAB) Price Target Lowered to $136.00 at JPMorgan Chase & Co. appeared first on ETF Daily News .